Tempus AI (NASDAQ:TEM) CFO Sells 22,529 Shares

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 22,529 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,117,663.69. Following the completion of the transaction, the chief financial officer owned 132,337 shares of the company’s stock, valued at $6,565,238.57. The trade was a 14.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Wednesday, August 19th, James William Rogers sold 26,313 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00.

Tempus AI Stock Performance

Tempus AI stock traded up $5.40 on Thursday, hitting $66.65. The company’s stock had a trading volume of 20,103,049 shares, compared to its average volume of 5,600,288. The firm has a market cap of $12.03 billion, a P/E ratio of -46.28 and a beta of 3.58. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a fifty day moving average price of $52.44 and a 200-day moving average price of $51.21. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.22) EPS. On average, equities analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on TEM. Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Freedom Capital upgraded Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Piper Sandler dropped their target price on Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a report on Tuesday, August 4th. Guggenheim raised their target price on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $65.69.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Tempus AI by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after purchasing an additional 817,014 shares during the last quarter. ARK Investment Management LLC boosted its position in Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in Tempus AI during the fourth quarter worth about $399,267,000. Sumitomo Mitsui Trust Group Inc. grew its stake in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after buying an additional 821,490 shares during the last quarter. Finally, Amova Asset Management Americas Inc. increased its holdings in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.